Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Espha Asks Patent Office to Invalidate Combination Patents for Takeda’s Actos
September 2, 2011
- Companies Responsible for Disclosure of Pharmacoeconomic Data: Chairman Eiki of Bayer Yakuhin
September 2, 2011
- Ontario Canada Supports Roche Canada’s New Research Site
September 2, 2011
- Sanofi Pasteur Appoints New GM
September 2, 2011
- Sanofi-aventis Nichi-Iko Applies for Cefotax Based on Public Data
September 1, 2011
- Wakamoto: Sales Up 2.1% Resulting in Smaller Losses
August 3, 2011
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…